The global oncology companion diagnostic market size is expected to reach USD 5.7 billion by 2027, expanding at a CAGR of 12.7%, according to a new report by Grand View Research, Inc. Expanding access to important genomic information with the aid of companion diagnostics enables informed decision making for designing the targeted treatment approaches for their patients, thereby increasing demand for comprehensive genomic testing and oncology companion diagnostics.
The
commercial launch of drugs including Gleevec (imatinib) and Herceptin
(trastuzumab) that require Companion Diagnostics (CDx) testing before
prescription has increased revenue generation in the oncology companion
diagnostics field. This growth is expected to continue in the future owing to a
substantial number of CDx associated oncology drugs in clinical trials.
Apart from functioning as exclusive or inclusive tests for therapies, CDx also
plays a crucial role during participant selection in clinical trials. This is
because there is an increased potential for a novel drug candidate to show a
better response rate if the patient has its biomarker target.
The
economic incentives associated with the use of CDx have encouraged drug
developers to combine their drugs with diagnostic tests. However, the
diagnostic manufacturers face conflicting demands from payers/providers on one
hand and drug manufacturers on the other hand. The regulatory bodies also have
stringent policies to align the development timelines of diagnostics and drugs.
Therefore, the diagnostic companies are expected to broaden their scope of CDx
development instead of focusing on the attainment of a match between a single
diagnostic with a specific drug.
Full Research Report On Oncology Companion Diagnostic Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/oncology-companion-diagnostics-market
Oncology Companion
Diagnostic Market Report Highlights
- The product
segment held the largest market share in 2019 owing to increased adoption
and usage rate of CDx tests
- A significant
increase in the approval rate of CDx and a rise in investments for
co-development of drugs and their CDx is expected to increase the revenue
generation in the product segment
- Consumables
occupied a major share of the product segment owing to the frequent use and
purchase of media, buffers, reagents, and other consumables required for
CDx assay
- Immunohistochemistry
(IHC) occupied a major portion of the technology segment owing to the
benefits offered by IHC technology including cost and time effectiveness,
the suitability of the technique for small tumor types, high adoption of
IHC for routine oncology CDx, and low technological requirements
associated with IHC
- Presence of a
substantial number of FDA approved IHC based CDx assays such as EGFR
pharmDx Kits, ER/PR pharmDx Kits, HercepTest Kits, PD-L1 IHC 28-8 pharmDx,
VENTANA PD-L1 (SP142) Assay, VENTANA ALK (D5F3) CDx Assay, and VENTANA ALK
IHC assay is also expected to increase revenue generation within the IHC
segment
- The Non-Small
Cell Lung Cancer (NSCLC) segment dominated the market in 2019 and is
expected to maintain its dominance during the forecast period
- NSCLC is a
lung cancer subtype that accounts for approximately 84.0% of all cases of
lung cancer. According to data published by the American Cancer Society
(ACS), in 2020, around 228,820 new cases of lung cancer are projected to
be diagnosed in the U.S.
- The breast
cancer and leukemia segments are expected to grow with substantial rates
owing to a rise in the number of cancer cases
- The hospital
segment held the largest share in the market in 2019 and is expected to
exhibit a considerable growth rate, owing to a rise in the number of
cancer diagnostic tests in the hospitals
- North America
dominated the market in 2019 owing to the presence of a substantial number
of players in this region, as well as the presence of a large number of
FDA-approved CDx solutions in cancer therapeutics
- Advancements
in technologies and improvements in the economic condition are anticipated
to drive the market at the fastest growth rate in the Asia Pacific
- The presence
of communities in Asian countries that are actively involved in monitoring
and discovery of genetic biomarkers is expected to positively influence
the market
- The key
players in the market are involved in mutually beneficial partnerships
with global entities, including sponsors and diagnostic commercialization
partners, which enables them to leverage their market potential globally.
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/oncology-companion-diagnostics-market/request/rs1
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment